Saturday 17 October 2026
Export PVLA’s income statement to Excel — free account
Palvella Therapeutics, Inc.
PVLA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 76.7% and free cash flow fell 136.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
120.30
7.04
−5.53%
Follow PVLA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (46.63%) | (34.25%) | (92.10%) | (117.82%) |
+8 more TTM periods Free account |
|
| (37.70%) | (28.73%) | (56.45%) | (74.02%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(25.59%) | (19.40%) | (87.56%) | (57.17%) | |
Average Days of Receivables |
— | — | — | 0.00 | |
Free Cash Flow per Share |
(2.54) | (2.22) | (2.22) | (2.30) | |
Free Cash Flow |
(36.51) | (29.10) | (25.01) | (25.47) | |
| Other line items | |||||
Cash ROIC |
(7.81%) | (5.89%) | (29.09%) | (24.91%) | |
Accounts Receivable Turnover |
— | — | — | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(7.60) | (6.86) | (6.63) | (5.88) | |
Operating CF/Net income |
0.59 | 0.59 | 0.60 | 0.79 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.54) | (2.22) | (2.22) | (2.30) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates